The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Open accessAbstract
BACKGROUND: Effective, well-tolerated oral psoriasis treatments are needed. OBJECTIVE: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis. METHODS: Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary end points included response rates for ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at week 16. RESULTS: At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001). Efficacy improved beyond week 16 and was maintained through week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast. LIMITATIONS: One-year duration, limited racial diversity. CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy end points and was well tolerated in moderate to severe plaque psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Papp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C., Stevens, R. M., Day, R. M., Gordon, K. B., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.03.049 · Cited by 678
Self-citationThe emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Self-citationPartial Impairment of Cytokine Responses in Tyk2-Deficient Mice
Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00054-6 · Cited by 420
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Papp, K., Gordon, K., Thaçi, D., Morita, A., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., & Banerjee, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806382 · Cited by 420
Self-citationBaker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Burke, J. R., Cheng, L., Gillooly, K. M., Strnad, J., Zupa-Fernandez, A., Catlett, I. M., Zhang, Y., Heimrich, E. M., McIntyre, K. W., Cunningham, M. D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1736 · Cited by 289
Janus kinases to jakinibs: from basic insights to clinical practice
Gadina, M., Le, M. T., Schwartz, D. M., Silvennoinen, O., Nakayamada, S., Yamaoka, K., & O’Shea, J. J. (2019) · Rheumatology · doi:10.1093/rheumatology/key432 · Cited by 173
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Nogueira, M., Puig, L., & Torres, T. (2020) · Drugs · doi:10.1007/s40265-020-01261-8 · Cited by 162
Fiorentino, D., Ho, V., Lebwohl, M. G., Leite, L., Hopkins, L., Galindo, C., Goyal, K., Langholff, W., Fakharzadeh, S., Srivastava, B., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.07.013 · Cited by 159
JAK inhibitors and infections risk: focus on herpes zoster
Sunzini, F., McInnes, I., & Siebert, S. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20936059 · Cited by 153
Sohn, S. J., Barrett, K., van Abbema, A., Chang, C. C., Kohli, P. B., Kanda, H., Smith, J. D., Lai, Y., Zhou, A., Zhang, B., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202859 · Cited by 144
Krueger, J. G., McInnes, I. B., & Blauvelt, A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.869 · Cited by 135
Self-citationSchurich, A., Raine, C., Morris, V., & Ciurtin, C. (2017) · Rheumatology · doi:10.1093/rheumatology/kex186 · Cited by 53
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Morand, E., Pike, M., Merrill, J. T., van Vollenhoven, R., Werth, V. P., Hobar, C., Delev, N., Shah, V., Sharkey, B., Wegman, T., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42391 · Cited by 266
Self-citationEczematized psoriasis – a frequent but often neglected variant of plaque psoriasis
Lauffer, F., & Eyerich, K. (2023) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14991 · Cited by 24
Metadata
- Authors
- Armstrong, A. W., Gooderham, M., Warren, R. B., Papp, K. A., Strober, B., Thaçi, D., Morita, A., Szepietowski, J. C., Imafuku, S., Colston, E., Throup, J., Kundu, S., Schoenfeld, S., Linaberry, M., Banerjee, S., & Blauvelt, A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 88
- Issue
- 1
- Pages
- 29-39
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W4284989117
- Cited by
- 372
- References
- 15
- FWCI
- 22.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.